Healthcare facility-onset, healthcare facility-associated Clostridioides difficile infection in Veterans with spinal cord injury and disorder.
Healthcare facility-onset, healthcare facility-associated Clostridioides difficile infection in Veterans with spinal cord injury and disorder.
复制标题
患有脊髓损伤和疾病的退伍军人中医疗机构发病、医疗机构相关的艰难梭菌感染。
DOI:
10.1080/10790268.2019.1672953
复制
发表时间:
2020
期刊:
影响因子:
--
通讯作者:
Johnson,Stuart
中科院分区:
文献类型:
--
作者:
Evans,CharlesnikaT;Fitzpatrick,Margaret;Ramanathan,Swetha;Kralovic,StephenM;Burns,StephenP;Goldstein,Barry;Smith,Bridget;Gerding,DaleN;Johnson,Stuart
Objective:To describe the burden and risk of healthcare facility-onset, healthcare facility-associated (HO-HCFA)Clostridioides difficileinfection (CDI) in Veterans with spinal cord injury and disorder (SCI/D).Design:Retrospective, longitudinal cohort study from October 1, 2001–September 30, 2010.Setting:Ninety-four acute care Veterans Affairs facilities.Participants:Patients with SCI/D.Outcomes:Incidence rate of HO-HCFA CDI.Methods:Rates of CDI were determined, and crude unadjusted incidence rate ratios (IRRs) and 95% confidence intervals (CIs) were calculated. Multivariable Poisson random-effects regression analyses were used to assess factors independently associated with the rate of CDI.Results:1,409 cases of HO-HCFA CDI were identified. CDI rates in 2002 were 13.9/10,000 person-days and decreased to 5.5/10,000 person-days by 2010. Multivariable regression analyses found that antibiotic (IRR = 18.79, 95% CI 14.09-25.07) and proton-pump inhibitor (PPI) or H2 blocker use (IRR = 7.71, 95% CI 5.47-10.86) were both independently associated with HO-HCFA CDI. Exposure to both medications demonstrated a synergistic risk (IRR = 37.55, 95% CI 28.39-49.67). Older age, Northeast region, and invasive respiratory procedure in the prior 30 days were also independent risk factors, while longer SCI duration and care at a SCI center were protective.Conclusion:Although decreasing, CDI rates in patients with SCI/D remain high. Targeted antimicrobial stewardship and pharmacy interventions that reduce antibiotic and PPI/H2 blocker use could have profound benefits in decreasing HO-HCFA CDI in this high-risk population.